Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls

Various nanomedicinal products (NMPs) have been reported to induce an adverse immune response, which may be related to their tendency to accumulate in or target cells of the immune system. Therefore, before their market authorization, NMPs should be thoroughly evaluated for their immunotoxic potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannakou, Christina, Park, Margriet V. D. Z., Bosselaers, Irene E. M., de Jong, Wim H., van der Laan, Jan Willem, van Loveren, Henk, Vandebriel, Rob J., Geertsma, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Advanced Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507198/
https://www.ncbi.nlm.nih.gov/pubmed/32266791
http://dx.doi.org/10.1002/wnan.1633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507198/
https://www.ncbi.nlm.nih.gov/pubmed/32266791
http://dx.doi.org/10.1002/wnan.1633

Ejemplares similares